Blueprint Medicines Corporation

Rigel Pharmaceuticals, Incorporated

Beni B Wolf

Erica Evans Raab

Disclosed herein are methods for treating a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 60 mg to 400 mg of the selective RET inhibitor once daily.

Growing community of inventors

Cambridge, MA, United States of America

Beni B Wolf